The synergistic antileukemic effects of eltrombopag and decitabine in myeloid leukemia cells

Medicine & Life Sciences

• eltrombopag 100%
• Decitabine 78%
• Myeloid Leukemia 74%
• Myeloid Cells 62%
• Myelodysplastic Syndromes 18%
• Acute Myeloid Leukemia 15%
• Reactive Oxygen Species 13%
• Leukemia 9%
• Cell Cycle 8%
• Thrombopoietin Receptors 8%
• G1 Phase Cell Cycle Checkpoints 7%
• Cell Cycle Resting Phase 6%
• G2 Phase 6%
• G1 Phase 5%
• Proxy 5%
• Cell Cycle Checkpoints 5%
• Platelet Count 5%
• Cell Division 5%
• Thrombocytopenia 5%
• Therapeutics 4%
• Cell Death 4%
• Cell Proliferation 3%
• Apoptosis 3%
• Cell Line 3%
• Drug Therapy 3%
• Growth 2%
• In Vitro Techniques 2%